Systemic Loss of FKBPL Uncovers Diabetes-Dependent Pathways of Myocardial and Vascular Injury
FKBPL plays an important role in glucose metabolism, endothelial function, angiogenesis, cardiac inflammation and function, and could be explored as a therapeutic target of cardiovascular disease both in nondiabetes and diabetes settings using precision medicine approach.
Authors
- Mary Meltem Kavurma (ORCID: https://orcid.org/0000-0001-7353-0932)
- Abdelrahim M. Alqudah (ORCID: https://orcid.org/0000-0003-3721-8225)
- Ross McNally (ORCID: https://orcid.org/0000-0002-9244-8683)
- David Grieve (ORCID: https://orcid.org/0000-0002-3655-7754)
- Karla O'Neill
- Amy Short
- Michael Chhor
- Kevin Edgar (ORCID: https://orcid.org/0000-0002-8057-0104)
- Sareh Zhand
- Lana McClements
- Guillermo Lopez-Campos
- Tracy Robson
- Natalie Le
Institutions
- University of Technology Sydney (AU)
- Queen's University Belfast (GB)
- Hashemite University (JO)
- The Heart Research Institute (AU)
- Texas Instruments (Ireland) (IE)
Publication Details
- Journal
- Arteriosclerosis Thrombosis and Vascular Biology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1161/atvbaha.125.323053
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00